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testinal ﬂora, and with a potential risk of gut colonization by
pathogens such as Candida species and vancomycin-resistant
enterococci [1]. We ﬁrst described the association between
candidaemia and severe Clostridium difﬁcile infection (CDI) [2,3];
the aim of this study was to investigate the risk factors and
clinical outcomes of patients developing nosocomial candidae-
mia after diagnosis of CDI.Materials and methodsStudy design and patients
This was a retrospective, case–control study of patients who
were admitted from January 2013 to December 2013 in three
large hospitals in Rome: Policlinico Umberto I, San Giovanni
Addolorata, and Policlinico Agostino Gemelli. All patients with
a documented CDI infection and subsequent nosocomial can-
didaemia were included in the study. The ethics committees
approved the study.
Study deﬁnitions
Concomitant infections were deﬁned according to the standard
CDC deﬁnitions [4]. Candidaemia was deﬁned as the isolation
of microorganisms in one or more separate blood cultures with
clinical evidence of infection [5,6]. Severe CDI was deﬁned as a
white blood cell count of >15 000 cells/μL and/or a serum
creatinine level 1.5 times the premorbid level [7].
Study groups
The obtainable records of all patients meeting the criteria for
CDI and candidaemia (Clostridium/Candida-positive) were stud-
ied, and the controls (Clostridium/Candida-negative) were cho-
sen at random from lists of patients hospitalized during the
same period in the same wards; the selection was based on the
need to create a homogeneous population to compare with the
Clostridium/Candida-positive group (case/control ratio of 3).
Microbiological analysis
Microbiological diagnosis of C. difﬁcile disease was performed by
the use of enzyme immunoassays combining detection of
C. difﬁcile glutamate dehydrogenase (GDH) and toxin A/B an-
tigens in stool specimens, with the commercial methods
TechLab C. Diff Quik Chek Complete or Meridian Bioscience
Immunocard C. difﬁcile GDH and Vidas C. difﬁcile Toxin A/B,
according to the testing algorithms established at the individualClin Microbiol Infect 2015; 21: 493.e1–493.e4
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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493.e2 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIstudy sites. All stool specimens were also tested with the
Cepheid Xpert C. difﬁcile/Epi assay, which is a multiplex real-
time PCR that detects tcdB, the binary toxin gene (cdt), and
the tcdC gene deletion at nucleotide 117, to identify the PCR-
ribotype 027 strain, also called the 027/NAP1/BI strain [8].
Blood specimens were processed with the automated
BACTEC system (Becton Dickinson Diagnostic Instruments,
Sparks, MD, USA).
Statistical analysis
The results obtained were analysed with a commercially avail-
able statistical software package (SPSS, version 20.0; SPSS,
Chicago, IL, USA). We used the chi-square test or Fisher exact
test for categorical variables, and the two-tailed t-test or
Mann–Whitney test for continuous variables, when appro-
priate. Statistical signiﬁcance was established at p  0.05. ATABLE 1. Clinical characteristics and outcomes of patients wit
univariate analysis
Variable
Clostridium/Can
n [ 35
Median age (years) 76.2 ± 7.2
Male sex, no. (%) 20 (57.1)
Presence of at least two comorbidities, no. (%) 35 (100)
COPD, no. (%) 12 (34.3)
Heart failure, no. (%) 11 (31.4)
Diabetes mellitus, no. (%) 13 (37.1)
Neoplasm, no. (%) 6 (17.1)
Chronic liver disease, no. (%) 3 (8.5)
Neurological disease, no. (%) 15 (42.9)
Immunosuppressive therapy, no. (%) 17 (48.5)
Chronic renal disease, no. (%) 12 (34.3)
IBD, no. (%) 3 (8.5)
Median Charlson Comorbidity Index 3.7 ± 1.5
Severe CDI, no. (%) 35 (100)
CDI relapse, no. (%) 29 (82.8)
Number of relapses >1, no. (%) 11 (31.4)
Ribotype 027 strain, no. (%) 28 (80)
Median Candida score 1.6 ± 0.3
Candida species, no. (%)
Candida albicans 17 (48.6)
Non-albicans Candida 18 (51.4)
Antibiotic therapy in previous 30 days, no. (%) 31 (88.6)
Median mean duration of previous antibiotic therapy (days) 10.1 ± 3.5
Median antifungal therapy in previous 30 days, no. (%) 5 (14.3)
Median mean duration of previous antifungal therapy (days) 7.1 ± 1.2
Removable intravascular devices, no. (%)
CVC 14 (40)
Pacemaker 3 (8.6)
CVC source of fungal infection, no. (%) 0
Other infections, no. (%) 4 (11.4)
Infections caused by MDR pathogens, no. (%) 4 (11.4)
Antibiotic regimen for primary CDI, no. (%)
Vancomycin 29 (82.9)
Metronidazole 6 (17.1)
Antibiotic regimen for CDI relapse, no. (%)
Vancomycin 19 (54.3)
Metronidazole 26 (74.2)
Vancomycin + metronidazole, no. (%) 10 (28.6)
Vancomycin 1000 mg/day, no. (%) 19 (54.3)
Median time at risk for CDI (days)a 9.4 ± 1.4
Median time at risk for CDI relapse (days)b 20.7 ± 4.3
Median duration of ICU stay (days) 15.9 ± 4.8
Median duration of hospital stay (days) 57.2 ± 19.9
In-hospital mortality, no. (%)
30-day 21 (60)
Overall 25 (71.5)
CDI, Clostridium difﬁcile infection; COPD, chronic obstructive pulmonary disease; CVC, cent
multidrug-resistant.
aTime at risk for CDI was considered to be the median of the time between hospitalization
bTime at risk for CDI relapse was considered to be the median of the time between the ﬁr
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmultivariate analysis was performed with a multiple logistic
regression model that included covariates with a p-value of
<0.20 in univariate analyses.ResultsThirty-ﬁve episodes of candidaemia subsequent to CDI were
recorded (63% were diagnosed in medical wards, 20% in
intensive-care units, and 17% in surgical wards). The cases were
compared with 105 patients with CDI, but with no microbio-
logical or clinical evidence of candidaemia during hospitalization.
Demographics, clinical features and outcomes of patients
included in the two groups are summarized in Tables 1 and 2.
Patients of the Clostridium/Candida-positive group showed more
severe CDI infection (including complications such as paralytich Clostridium/Candida infection as compared with controls:
dida-positive, Clostridium/Candida-negative,
n [ 105 p
76 ± 7.9 0.9
59 (56.2) 0.2
102 (97.1) 0.2
33 (31.4) 0.09
30 (28.6) 0.08
33 (31.4) 0.07
19 (18) 0.6
11 (10.4) 0.08
43 (40.9) 0.08
29 (27.6) 0.01
39 (37.1) 0.09
0 0.03
3.4 ± 1.6 0.3
45 (42.8) <0.001
28 (26.6) <0.001
6 (5.7) <0.001
37 (35) <0.001
1.4 ± 0.3 0.09
— —
— —
94 (89.5) 0.09
9.2 ± 2.9 0.06
12 (11.4) 0.07
5.3 ± 0.8 0.01
41 (39) 0.6
11 (10.4) 0.7
0 —
13 (12.4) 0.8
6 (5.7) 0.002
88 (83.8) 0.3
17 (16.2) 0.4
54 (51.4) 0.07
79 (75.2) 0.5
28 (26.7) 0.1
31 (29.5) 0.01
10.1 ± 2.3 0.8
33.1 ± 5.7 <0.001
9.2 ± 3.9 <0.001
28.3 ± 12.2 <0.001
14 (13.3) <0.001
21 (20) <0.001
ral venous catheter; IBD, inﬂammatory bowel disease; ICU, intensive-care unit; MDR,
and the clinical development of CDI.
st CDI and the relapse of infection.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 493.e1–493.e4
TABLE 2. Clinical characteristics and outcomes of patients
with Clostridium/Candida infection as compared with
controls: multivariate analysis
Variable OR 95% CI p
Ribotype 027 strain 4.5 2.89–7.12 0.001
CDI relapse 5.9 3.91–9.23 <0.001
Severe CDI infection 4.4 2.76–6.12 <0.001
Number of relapses >1 3.1 1.93–5.12 <0.001
Vancomycin 1000 mg/day 2.1 1.87–2.95 0.01
Immunosuppressive therapy 2.2 1.45–4.23 0.02
CDI, Clostridium difﬁcile infection.
CMI Russo et al. Candidaemia subsequent to Clostridium difﬁcile infection 493.e3ileus, intensive-care unit admission, and/or hypoalbuminaemia)
and were more frequently diagnosed with CDI relapsing
infection. There were no cases of central venous catheter-
related candidaemia.
The ribotype 027 strain was found in 28 (80%) patients of
the Clostridium/Candida-positive group, and in 37 (35%) patients
of the Clostridium/Candida-negative group (p < 0.001). The
median time at risk for candidaemia was 15.3 ± 3.9 days, but
almost all patients with CDI due to the ribotype 027 strain
developed candidaemia within 2 weeks from CDI diagnosis
(93% vs. 20%, p < 0.001; Fig. 1). Vancomycin was the most
commonly used antibiotic regimen for the primary CDI; a
vancomycin dose of 1000 mg/day was more frequently used
in the Clostridium/Candida-positive group.
CDI patients who developed candidaemia had higher 30-day
and overall in-hospital mortality than controls. The multivariate
analysis showed ribotype 027, CDI relapse, severe CDI, num-
ber of relapses >1, vancomycin 1000 mg/day and immuno-
suppressive therapy as risk factors independently associated
with the development of candidaemia.DiscussionTo our knowledge, this is the ﬁrst study showing an association
between severe CDI and nosocomial candidaemia. The keyFIG. 1. Risk of Candida bloodstream infection in patients with or
without the ribotype 027 strain.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inpoints of our study could be summarized as follows: (a) CDI
may predispose to translocation of Candida species from the
intestinal lumen to the blood; (b) this mechanism is directly
associated with severe CDI and/or CDI relapses, probably
because of a high degree of impairment of the normal intestinal
microbiota; and (c) CDI due to the ribotype 027 strain is as an
independent risk factor for the development of candidaemia
after CDI, and is associated with a poor outcome.
The disruption of the community of commensal microor-
ganisms in the intestinal lumen of patients with CDI may allow
Candida colonization. Nerandzic et al. analysed 301 patients
with CDI, and found that 16% of patients had positive stool
cultures for Candida species and 18% for vancomycin-resistant
enterococci prior to CDI treatment [1]. Raponi et al. [9]
found that CDI was signiﬁcantly associated with Candida colo-
nization (83% CDI-positive vs. 67% CDI-negative; p < 0.05),
with Candida albicans being the species most often implicated.
Thus, intestinal colonization from Candida species appears to be
the key factor for subsequent seeding of Candida in the blood.
Selection of Candida may also be promoted by CDI treat-
ments; oral vancomycin or metronidazole may disrupt the
already abnormal ﬂora, and thereby enhance the growth of any
resident microorganism. Warren et al. [10] found that
vancomycin-treated infected mice were highly susceptible to
severe disease, resulting in overall mortality rates at least
similar to those of untreated infected controls; vancomycin led
not only to C. difﬁcile overgrowth, clostridial predominance
over the commensal anaerobes (e.g. Bacteroides species), and a
high rate of recurrence, but also to delayed intestinal tissue
injury, which may act as an additional driver for microbial
translocation. Importantly, we recognized that high doses of
vancomycin (1000 mg/day) constitute an independent risk
factor for the development of Candida bloodstream infection.
Severe CDI is characterized by an intense host inﬂammatory
response, provoked by toxin hyperproduction [11]; toxin
production is directly involved in intestinal mucosal epithelium
injury [12,13], and also causes mucosal immunity impairment by
modiﬁcation of neutrophil morphology and function [14]. In
recent years, an increasing incidence of the ribotype 027 strain
has been reported in our geographical area [15], and there is
epidemiological evidence for the recent spread of this organism
in our hospital [16]. CDI due to the ribotype 027 strain
probably causes increased damage to the integrity of the in-
testinal mucosa, and may promote Candida translocation. All of
these ﬁndings may explain why infection due to the ribotype
027 strain was independently associated with the development
of candidaemia.
There are two important limitations of our study: ﬁrst,
possible Candida intestinal colonization preceding CDI was not
assessed in our patients; and second, the population analysedfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 493.e1–493.e4
493.e4 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIwas too small for deﬁnitive conclusions to be drawn, and our
study was not adequately powered or designed to validate this
hypothesis.
In conclusion, patients with severe or relapsed CDI are at
increased risk of nosocomial candidaemia with a poor clinical
outcome. Our study also highlights the possible role of the
ribotype 027 strain and its potential relationship with increased
vancomycin dosage, suggesting the need for new treatment
options in patients with severe CDI.Transparency declarationThe authors declare no conﬂicts of interest.AcknowledgementsNo funding was received for this study. We give special thanks
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